These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1213 related articles for article (PubMed ID: 27250110)
21. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
22. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes]. Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797 [TBL] [Abstract][Full Text] [Related]
23. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
24. Chemosensitization of doxorubicin in multidrug-resistant cells by unimolecular micelles via increased cellular accumulation and apoptosis. Wang M; Han M; Li Y; Jin Y; Gao JQ J Pharm Pharmacol; 2016 Mar; 68(3):333-41. PubMed ID: 26893058 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Wong HL; Bendayan R; Rauth AM; Wu XY J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178 [TBL] [Abstract][Full Text] [Related]
26. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Zhang ZL; Jiang QC; Wang SR Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822 [TBL] [Abstract][Full Text] [Related]
27. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173 [TBL] [Abstract][Full Text] [Related]
28. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920 [TBL] [Abstract][Full Text] [Related]
29. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123 [TBL] [Abstract][Full Text] [Related]
30. Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance. Shi C; Zhang Z; Shi J; Wang F; Luan Y Int J Pharm; 2015 Nov; 495(2):932-9. PubMed ID: 26456262 [TBL] [Abstract][Full Text] [Related]
31. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance. Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761 [TBL] [Abstract][Full Text] [Related]
32. Targeted multidrug delivery system to overcome chemoresistance in breast cancer. Tang Y; Soroush F; Tong Z; Kiani MF; Wang B Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940 [TBL] [Abstract][Full Text] [Related]
33. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway. Wang Z; Yang L; Xia Y; Guo C; Kong L Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987 [TBL] [Abstract][Full Text] [Related]
34. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance. Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118 [TBL] [Abstract][Full Text] [Related]
35. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction. Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453 [TBL] [Abstract][Full Text] [Related]
36. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer. Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756 [TBL] [Abstract][Full Text] [Related]
37. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738 [TBL] [Abstract][Full Text] [Related]
38. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Krishna R; Mayer LD Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743 [TBL] [Abstract][Full Text] [Related]
39. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799 [TBL] [Abstract][Full Text] [Related]
40. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]